Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBIT Margin: 2020-2025

Historic EBIT Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to 1.96%.

  • Mirum Pharmaceuticals' EBIT Margin rose 1599.00% to 1.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -8.86%, marking a year-over-year increase of 2240.00%. This contributed to the annual value of -26.00% for FY2024, which is 3256.00% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its EBIT Margin stood at 1.96% for Q3 2025, which was up 150.13% from -3.90% recorded in Q2 2025.
  • Mirum Pharmaceuticals' EBIT Margin's 5-year high stood at 1,408.25% during Q1 2021, with a 5-year trough of -1,452.36% in Q4 2021.
  • In the last 3 years, Mirum Pharmaceuticals' EBIT Margin had a median value of -31.12% in 2024 and averaged -33.95%.
  • Its EBIT Margin has fluctuated over the past 5 years, first slumped by 1,248,251bps in 2021, then skyrocketed by 132,994bps in 2022.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' EBIT Margin stood at -1,452.36% in 2021, then skyrocketed by 132,994bps to -122.41% in 2022, then skyrocketed by 7,557bps to -46.85% in 2023, then surged by 2,248bps to -24.36% in 2024, then skyrocketed by 1,599bps to 1.96% in 2025.
  • Its EBIT Margin was 1.96% in Q3 2025, compared to -3.90% in Q2 2025 and -13.61% in Q1 2025.